company background image
EXL

Elixinol WellnessASX:EXL Stock Report

Market Cap

AU$28.4m

7D

-3.2%

1Y

-40.0%

Updated

18 Oct, 2021

Data

Company Financials
EXL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

EXL Overview

Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia.

Elixinol Wellness Competitors

Charlotte's Web Holdings

TSX:CWEB

CA$325.7m

CV Sciences

OTCPK:CVSI

US$27.4m

Price History & Performance

Summary of all time highs, changes and price drops for Elixinol Wellness
Historical stock prices
Current Share PriceAU$0.09
52 Week HighAU$0.087
52 Week LowAU$0.36
Beta0.96
1 Month Change-14.29%
3 Month Change-25.00%
1 Year Change-40.00%
3 Year Change-94.92%
5 Year Changen/a
Change since IPO-93.79%

Recent News & Updates

Sep 27
Here's Why We're Watching Elixinol Wellness' (ASX:EXL) Cash Burn Situation

Here's Why We're Watching Elixinol Wellness' (ASX:EXL) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Jun 02
We're Keeping An Eye On Elixinol Wellness' (ASX:EXL) Cash Burn Rate

We're Keeping An Eye On Elixinol Wellness' (ASX:EXL) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

EXLAU Personal ProductsAU Market
7D-3.2%2.4%0.9%
1Y-40.0%17.0%20.2%

Return vs Industry: EXL underperformed the Australian Personal Products industry which returned 17% over the past year.

Return vs Market: EXL underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is EXL's price volatile compared to industry and market?
EXL volatility
EXL Beta0.96
Industry Beta0.70
Market Beta1

Stable Share Price: EXL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: EXL's weekly volatility has decreased from 15% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aOliver Hornhttps://www.elixinolwellness.com

Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021.

Elixinol Wellness Fundamentals Summary

How do Elixinol Wellness's earnings and revenue compare to its market cap?
EXL fundamental statistics
Market CapAU$28.39m
Earnings (TTM)-AU$25.03m
Revenue (TTM)AU$11.95m

2.4x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EXL income statement (TTM)
RevenueAU$11.95m
Cost of RevenueAU$5.72m
Gross ProfitAU$6.23m
ExpensesAU$31.27m
Earnings-AU$25.03m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.079
Gross Margin52.16%
Net Profit Margin-209.47%
Debt/Equity Ratio1.0%

How did EXL perform over the long term?

See historical performance and comparison

Valuation

Is Elixinol Wellness undervalued compared to its fair value and its price relative to the market?

1.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EXL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EXL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EXL is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.

PE vs Market: EXL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EXL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EXL is good value based on its PB Ratio (1.1x) compared to the AU Personal Products industry average (2.9x).


Future Growth

How is Elixinol Wellness forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.0%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elixinol Wellness has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Elixinol Wellness performed over the past 5 years?

-46.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EXL is currently unprofitable.

Growing Profit Margin: EXL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EXL is unprofitable, and losses have increased over the past 5 years at a rate of 46.7% per year.

Accelerating Growth: Unable to compare EXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EXL is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).


Return on Equity

High ROE: EXL has a negative Return on Equity (-99.31%), as it is currently unprofitable.


Financial Health

How is Elixinol Wellness's financial position?


Financial Position Analysis

Short Term Liabilities: EXL's short term assets (A$24.2M) exceed its short term liabilities (A$4.2M).

Long Term Liabilities: EXL's short term assets (A$24.2M) exceed its long term liabilities (A$1.8M).


Debt to Equity History and Analysis

Debt Level: EXL's debt to equity ratio (1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if EXL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EXL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EXL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13% each year


Dividend

What is Elixinol Wellness's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EXL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Oliver Horn (49 yo)

1.5yrs

Tenure

AU$534,782

Compensation

Mr. Oliver Horn serves Global Chief Executive Officer at Elixinol Wellness Limited (formerly known as Elixinol Global Limited) since 2021 and served as Group Chief Executive Officer since April 21, 2020 un...


CEO Compensation Analysis

Compensation vs Market: Oliver's total compensation ($USD396.93K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Insufficient data to compare Oliver's compensation with company performance.


Leadership Team

Experienced Management: EXL's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: EXL's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 63.7%.


Top Shareholders

Company Information

Elixinol Wellness Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Elixinol Wellness Limited
  • Ticker: EXL
  • Exchange: ASX
  • Founded: 2017
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: AU$28.390m
  • Shares outstanding: 315.44m
  • Website: https://www.elixinolwellness.com

Location

  • Elixinol Wellness Limited
  • 680 George Street
  • Level 12
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:03
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.